Loading
A phase 2 trial of Intismeran autogene, Pembrolizumab in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). is a phase 2 interventional study registered as NCT06307431 by Merck Sharp & Dohme LLC, with 272 participants planned, started 2024-04-10 and due to reach its primary completion in 2028-01-08. Interventions recorded: Intismeran autogene, Pembrolizumab, Placebo. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD).
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD).
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Pembrolizumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/